WordNet

(medicine) the act of caring for someone (as by medication or remedial training etc.); "the quarterback is undergoing treatment for a knee injury"; "he tried every treatment the doctors suggested"; "heat therapy gave the best relief"
an anticoagulant (trade name Coumadin) use to prevent and treat a thrombus or embolus (同)Coumadin

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Contemporary developments in the discovery of selective factor Xa inhibitors: A review.

Patel NR1, Patel DV1, Murumkar PR1, Yadav MR2.
European journal of medicinal chemistry.Eur J Med Chem.2016 Oct 4;121:671-98. doi: 10.1016/j.ejmech.2016.05.039. Epub 2016 May 24.
Thrombosis is a leading cause of death in cardiovascular diseases such as myocardial infarction (MI), unstable angina and acute coronary syndrome (ACS) in the industrialized world. Venous thromboembolism is observed in about 1 million people every year in United States causing significant morbidity
PMID 27322757

A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation.

Obamiro KO1, Chalmers L2, Bereznicki LR2.
American journal of cardiovascular drugs : drugs, devices, and other interventions.Am J Cardiovasc Drugs.2016 Oct;16(5):349-63. doi: 10.1007/s40256-016-0171-6.
Atrial fibrillation (AF) is a growing public health concern and remains an independent risk factor for ischemic stroke. Warfarin, a commonly used oral anticoagulant, is associated with a 60-70 % relative reduction in stroke risk and a reduction in mortality of 26 %. However, warfarin has several l
PMID 27262433

Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.

Acanfora D1, Acanfora C1, Scicchitano P2, Longobardi M1, Furgi G1, Casucci G3, Lanzillo B1, Dentamaro I2, Zito A2, Incalzi RA4, Ciccone MM5.
Clinical drug investigation.Clin Drug Investig.2016 Oct;36(10):857-62. doi: 10.1007/s40261-016-0436-5.
BACKGROUND AND OBJECTIVES: The new oral anticoagulants (NOACs) are used for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) and those at risk of deep venous thrombosis. Their rapid onset of action and predictable pharmacokinetic and pharmacodyna
PMID 27401780